Prometheus Taps Conatus’s Marshall as Its Chief Financial Officer

Prometheus Biosciences has appointed Keith Marshall its chief financial officer. Marshall most recently served as chief operating officer and CFO at Conatus Pharmaceuticals, which earlier this year merged with Histogen (NASDAQ: [[ticker:HSTO]]). Before Conatus, Marshall was CFO and head of corporate development at Flagship Pioneering spinout Torque Therapeutics, since renamed Repertoire Immune Medicines. Marshall started his career in investment banking.

San Diego-based Prometheus is developing targeted therapies for inflammatory bowel disease. The company, formerly known as Precision IBD, last year acquired a gastrointestinal disease diagnostics unit called Prometheus Laboratories from Nestlé Health Science and after combining the firms, debuted the new name.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.